.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,348,210

« Back to Dashboard

Claims for Patent: 6,348,210

Title: Methods for transdermal drug administration
Abstract:Adhesive transdermal drug delivery devices may be removed and subsequently reapplied to an area of skin if the adhesive has an initial adhesive/skin bond strength sufficient to maintain said transdermal drug delivery device on the skin to which it is applied for the entire predetermined administration period; and an adhesive/skin bond strength upon replacement on the skin after removal therefrom which is adequate to retain the device on the skin for the balance of the administration period.
Inventor(s): Gale; Robert Martin (Los Altos, CA)
Assignee: Alza Corporation (Mountain View, CA)
Application Number:09/438,574
Patent Claims: 1. A method for transdermal administration of a drug through non-scrotal skin over a predetermined administration period comprising:

a) placing a transdermal drug delivery device containing the drug and having an adhesive surface for maintaining the device on non-scrotal skin of an individual;

b) removing said device from the skin prior to the expiration of said period; and

c) reapplying said device on the non-scrotal skin of the individual;

d) wherein said adhesive surface is formed from an adhesive formulation that provides (i) an initial adhesive/skin bond strength sufficient to maintain said transdermal drug delivery device on the non-scrotal skin to which it is applied for the entire predetermined administration period and (ii) an adhesive/skin bond strength upon replacement on non-scrotal skin sufficient to retain said device for the balance of said administration period.

2. The method of claim 1 wherein said initial bond strength is less than 195 gm/cm.

3. The method of claim 2 wherein the initial bond strength is at least about 95 gm/cm.

4. The method of claim 2 wherein said adhesive formulation is a non-cross-linked adhesive formulation.

5. The method of claim 4 wherein the non-cross-linked adhesive polymer is polyisobutylene (PIB).

6. The method according to claim 1 wherein the adhesive surface comprises a mixture of low molecular weight polyisobutylene (LMW PIB) and high molecular weight polyisobutylene (HMW PIB).

7. A method according to claim 6 wherein the low molecular weight polyisobutylene (LMW PIB) has a molecular weight of about 15,000-50,000 and the high molecular weight polyisobutylene (HMW PIB) has a molecular weight of about 990,000-1,6000,000.

8. A method according to claim 7 wherein the adhesive further comprises a plasticizer.

9. A method according to claim 8 wherein high molecular weight polyisobutylene (HMW PIB)/low molecular weight polyisobutylene (LMW PIB)/plasticizer ratio is: 0.75-1.25/1-1.5/1.5-2.5.

10. The method of claim 2 wherein the adhesive/skin bond strength on replacement is at least 72% of said initial bond strength.

11. The method of claim 10 when the adhesive/skin bond strength on replacement is at least 85% of said initial bond strength.

12. The method of claim 3 wherein said adhesive/skin bond strength on replacement is at least 72% of said initial bond strength.

13. The method of claim 12 wherein the adhesive/skin bond strength on replacement is at least 85% of said initial bond strength.

14. The method of claim 9 wherein the plasticizer is selected from the group consisting of mineral oil and polybutene.

15. The method of claim 1 wherein said drug is testosterone.

16. The method of claim 3 wherein said drug is testosterone.

17. The method of claim 13 wherein said drug is testosterone.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc